A clinical trial revealed that Eli Lilly's oral drug orforglipron is as effective in lowering blood sugar and aiding weight loss in Type 2 diabetes patients as popular injectable drugs like Ozempic and Mounjaro. This daily pill offers a more convenient alternative to injections, potentially increasing accessibility for millions. In a trial with 559 participants, blood sugar levels decreased significantly, with 65% achieving normal levels. Weight loss was also notable, while side effects remained consistent with current GLP-1 treatments. The findings suggest a shift towards more user-friendly options in diabetes management.
The drug orforglipron, a GLP-1 pill, has shown comparable efficacy to injectable diabetes treatments in lowering blood sugar and facilitating weight loss in a clinical trial.
Dr. Daniel Skovronsky emphasized the importance of developing accessible treatments for diabetes, stating that with rising global rates of obesity and diabetes, injections cannot be the solution for everyone.
Collection
[
|
...
]